Hologic News

StockCall.com Provides Stock Research on St. Jude Medical Inc., Hologic Inc., Navidea Biopharmaceuticals Inc., Edwards Lifesciences Corp., and ResMed Inc.

They currently have a $23.00 target price on the stock, down from their previous target price of $27.00. Hologic traded up 3.27% on Tuesday, hitting $21.18. Hologic has a 52-week low of $16.18 and a 52-week high of $23.96. The stock's 50-day moving average is currently $21.99. The company's market cap is $5.680 billion.

's stock had its "neutral" rating reaffirmed by Zacks in a report released on Thursday, AnalystRatingsNetwork.com reports.

Hologic , a manufacturer of diagnostics products, medical imaging systems and surgical products has appointed Scott T. Garrett to the Company's newly expanded board of directors.

I have no qualms with those who believe it is the responsibility of the management of public companies to communicate clearly and accurately with investors about the current state of the business and the likely near-term conditions.

As a leading provider of free in depth reports and timely market updates, Paragon is an essential resource for hundreds of thousands of investors across the country.

The firm currently has a "buy" rating on the stock. A number of other firms have also recently commented on HOLX.

Good day, everyone, and welcome to the Hologic Inc. Second Quarter Fiscal 2013 Earnings Conference Call.

Hologic updated its FY13 earnings guidance on Monday. The company provided earnings per share guidance of $1.54-1.56 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.58, AnalystRatingsNetwork.com reports.

Hologic announced its earnings results on Monday. The company reported $0.35 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.34 by $0.01, Stock Ratings Network reports.

The presentation will be available on DiagnoCure's website at www.diagnocure.com through a link on the Investors page; presentations, available from DiagnoCure is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions.